文献速递物质与行为成瘾会诊联络精神医学

慢性疼痛、大麻合法化与退伍军人健康管理局患者大麻使用障碍(2005–2019):重复横断面研究

Chronic pain, cannabis legalisation, and cannabis use disorder among patients in the US Veterans Health Administration system, 2005 to 2019: a repeated, cross-sectional study.
PubMed 文献 · Lancet Psychiatry · 2023-10-11

该研究基于美国退伍军人健康管理局2005–2019年15个重复横断面电子健康记录数据集,采用交错采纳双重差分分析,评估医疗大麻法(MCL)和娱乐大麻法(RCL)实施对慢性疼痛患者大麻使用障碍患病率的影响。

要点

  • MCL和RCL与大麻使用障碍的关联在慢性疼痛患者中大于无慢性疼痛患者。

核心结论

  • 州大麻合法化后慢性疼痛患者大麻使用障碍患病率增加,构成公共卫生关注点,尤其在老年群体中。
  • 鉴于大麻商业化和公众对其疗效的普遍信念,建议对慢性疼痛患者进行大麻使用临床监测并讨论大麻使用障碍风险。

研究设计与样本

  • 研究分析了2005–19年至少一次初级保健、急诊或精神健康就诊的VHA患者数据,使用15个重复横断面VHA电子健康记录数据集(每年一个数据集)。
  • 排除临终关怀或姑息治疗患者,使用美国疼痛学会疼痛医学状况分类法将患者分为有或无慢性疼痛。
  • 采用交错采纳双重差分分析,通过按疼痛分层的线性二项回归模型估计MCL和RCL实施的作用,模型包含时变大麻法状态、州固定效应、分类年份、时变州级社会人口学协变量和患者协变量(年龄组[18-34岁、35-64岁、65-75岁]、性别、种族和民族)。

临床怎么用

  • 对慢性疼痛患者应进行大麻使用临床监测,并讨论大麻使用障碍风险,尤其关注老年群体。
  • 在评估慢性疼痛患者时,考虑州大麻合法化状态对患者大麻使用障碍风险的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cannabis use disorder is associated with considerable comorbidity and impairment in functioning, and prevalence is increasing among adults with chronic pain. We aimed to assess the effect of introduction of medical cannabis laws (MCL) and recreational cannabis laws (RCL) on the increase in cannabis use disorder among patients in the US Veterans Health Administration (VHA). METHODS: Data from patients with one or more primary care, emergency, or mental health visit to the VHA in 2005-19 were analysed using 15 repeated cross-sectional VHA electronic health record datasets (ie, one dataset per year). Patients in hospice or palliative care were excluded. Patients were stratified as having chronic pain or not using an American Pain Society taxonomy of painful medical conditions. We used staggered-adoption difference-in-difference analyses to estimate the role of MCL and RCL enactment in the increases in prevalence of diagnosed cannabis use disorder and associations with presence of chronic pain, accounting for the year that state laws were enacted. We did this by fitting a linear binomial regression model stratified by pain, with time-varying cannabis law status, fixed effects for state, categorical year, time-varying state-level sociodemographic covariates, and patient covariates (age group [18-34 years, 35-64 years, and 65-75 years], sex, and race and ethnicity). FINDINGS: Between 2005 and 2019, 3 234 382-4 579 994 patients were included per year. Among patients without pain in 2005, 5·1% were female, mean age was 58·3 (SD 12·6) years, and 75·7%, 15·6%, and 3·6% were White, Black, and Hispanic or Latino, respectively. In 2019, 9·3% were female, mean age was 56·7 (SD 15·2) years, and 68·1%, 18·2%, and 6·5% were White, Black, and Hispanic or Latino, respectively. Among patients with pain in 2005, 7·1% were female, mean age was 57·2 (SD 11·4) years, and 74·0%, 17·8%, and 3·9% were White, Black, and Hispanic or Latino, respectively. In 2019, 12·4% were female, mean age was 57·2 (SD 13·8) years, and 65·3%, 21·9%, and 7·0% were White, Black, and Hispanic or Latino, respectively. Among patients with chronic pain, enacting MCL led to a 0·135% (95% CI 0·118-0·153) absolute increase in cannabis use disorder prevalence, with 8·4% of the total increase in MCL-enacting states attributable to MCL. Enacting RCL led to a 0·188% (0·160-0·217) absolute increase in cannabis use disorder prevalence, with 11·5% of the total increase in RCL-enacting states attributable to RCL. In patients without chronic pain, enacting MCL and RCL led to smaller absolute increases in cannabis use disorder prevalence (MCL: 0·037% [0·027-0·048], 5·7% attributable to MCL; RCL: 0·042% [0·023-0·060], 6·0% attributable to RCL). Overall, associations of MCL and RCL with cannabis use disorder were greater in patients with chronic pain than in patients without chronic pain. INTERPRETATION: Increasing cannabis use disorder prevalence among patients with chronic pain following state legalisation is a public health concern, especially among older age groups. Given cannabis commercialisation and widespread public beliefs about its efficacy, clinical monitoring of cannabis use and discussion of the risk of cannabis use disorder among patients with chronic pain is warranted. FUNDING: NIDA grant R01DA048860, New York State Psychiatric Institute, and the VA Centers of Excellence in Substance Addiction Treatment and Education.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Hasin DS, Wall MM, Alschuler DM, et al. Chronic pain, cannabis legalisation, and cannabis use disorder among patients in the US Veterans Health Administration system, 2005 to 2019: a repeated, cross-sectional study. Lancet Psychiatry. 2023. PMID: 37837985. doi:10.1016/S2215-0366(23)00268-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。